JP2005526850A5 - - Google Patents

Download PDF

Info

Publication number
JP2005526850A5
JP2005526850A5 JP2004505094A JP2004505094A JP2005526850A5 JP 2005526850 A5 JP2005526850 A5 JP 2005526850A5 JP 2004505094 A JP2004505094 A JP 2004505094A JP 2004505094 A JP2004505094 A JP 2004505094A JP 2005526850 A5 JP2005526850 A5 JP 2005526850A5
Authority
JP
Japan
Prior art keywords
disease
diabetic
failure
aliskiren
amlodipine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2004505094A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005526850A (ja
JP5288678B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2003/005188 external-priority patent/WO2003097098A1/en
Publication of JP2005526850A publication Critical patent/JP2005526850A/ja
Publication of JP2005526850A5 publication Critical patent/JP2005526850A5/ja
Application granted granted Critical
Publication of JP5288678B2 publication Critical patent/JP5288678B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2004505094A 2002-05-17 2003-05-16 レニンインヒビター、カルシウムチャネルブロッカーおよび利尿薬を含む医薬組成物 Expired - Fee Related JP5288678B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38154602P 2002-05-17 2002-05-17
US60/381,546 2002-05-17
PCT/EP2003/005188 WO2003097098A1 (en) 2002-05-17 2003-05-16 Pharmaceutical composition comprising a renin inhibitor, a calcium channel blocker and a diuretic

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010181380A Division JP2010280708A (ja) 2002-05-17 2010-08-13 レニンインヒビター、カルシウムチャネルブロッカーおよび利尿薬を含む医薬組成物

Publications (3)

Publication Number Publication Date
JP2005526850A JP2005526850A (ja) 2005-09-08
JP2005526850A5 true JP2005526850A5 (cg-RX-API-DMAC7.html) 2010-04-22
JP5288678B2 JP5288678B2 (ja) 2013-09-11

Family

ID=29550141

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2004505094A Expired - Fee Related JP5288678B2 (ja) 2002-05-17 2003-05-16 レニンインヒビター、カルシウムチャネルブロッカーおよび利尿薬を含む医薬組成物
JP2010181380A Withdrawn JP2010280708A (ja) 2002-05-17 2010-08-13 レニンインヒビター、カルシウムチャネルブロッカーおよび利尿薬を含む医薬組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010181380A Withdrawn JP2010280708A (ja) 2002-05-17 2010-08-13 レニンインヒビター、カルシウムチャネルブロッカーおよび利尿薬を含む医薬組成物

Country Status (24)

Country Link
US (3) US20050182042A1 (cg-RX-API-DMAC7.html)
EP (2) EP2316488A1 (cg-RX-API-DMAC7.html)
JP (2) JP5288678B2 (cg-RX-API-DMAC7.html)
KR (3) KR20100137026A (cg-RX-API-DMAC7.html)
CN (1) CN1655819A (cg-RX-API-DMAC7.html)
AT (1) ATE520417T1 (cg-RX-API-DMAC7.html)
AU (1) AU2003240669B2 (cg-RX-API-DMAC7.html)
BR (1) BR0310084A (cg-RX-API-DMAC7.html)
CA (1) CA2485081C (cg-RX-API-DMAC7.html)
CY (2) CY1112013T1 (cg-RX-API-DMAC7.html)
DK (1) DK1507558T3 (cg-RX-API-DMAC7.html)
EC (1) ECSP045428A (cg-RX-API-DMAC7.html)
ES (1) ES2369216T3 (cg-RX-API-DMAC7.html)
IL (1) IL164837A (cg-RX-API-DMAC7.html)
LU (1) LU92000I2 (cg-RX-API-DMAC7.html)
MX (1) MXPA04011383A (cg-RX-API-DMAC7.html)
NO (1) NO334382B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ536555A (cg-RX-API-DMAC7.html)
PL (1) PL219032B1 (cg-RX-API-DMAC7.html)
PT (1) PT1507558E (cg-RX-API-DMAC7.html)
RU (1) RU2316318C2 (cg-RX-API-DMAC7.html)
SI (1) SI1507558T1 (cg-RX-API-DMAC7.html)
WO (1) WO2003097098A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200408442B (cg-RX-API-DMAC7.html)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
US8168616B1 (en) * 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
KR20100137026A (ko) * 2002-05-17 2010-12-29 노파르티스 아게 레닌 억제제, 칼슘 채널 차단제 및 이뇨제를 포함하는 약제학적 조성물
WO2004110354A2 (en) 2003-05-15 2004-12-23 Roskamp Research, Llc Method for reducing amyloid deposition, amyloid neurotoxicity and microgliosis
TW200538154A (en) * 2004-02-17 2005-12-01 Novartis Ag Combination of organic compounds
RU2426532C2 (ru) * 2004-03-17 2011-08-20 Новартис Аг Применение органических соединений
MY144477A (en) * 2004-03-17 2011-09-30 Novartis Ag Galenic formulations of organic compounds
ES2257152B1 (es) * 2004-05-31 2007-07-01 Laboratorios Almirall S.A. Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
RU2385156C2 (ru) * 2004-05-31 2010-03-27 Лабораториос Альмираль С.А. Комбинации, содержащие антимускариновые средства и кортикостероиды
MY146830A (en) * 2005-02-11 2012-09-28 Novartis Ag Combination of organic compounds
MX2007011697A (es) * 2005-03-22 2007-11-16 Novartis Ag Biomarcadores para eficacia de aliskiren como agente hipertensivo.
EP1951309A2 (en) * 2005-11-08 2008-08-06 Novartis AG Combination of an angiotensin ii receptor blocker, a calcium channel blocker and another active agent
AR057882A1 (es) 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
GB0612540D0 (en) * 2006-06-23 2006-08-02 Novartis Ag Galenical formulations of organic compounds
EP1891937A1 (en) * 2006-08-25 2008-02-27 Novartis AG Galenic formulations of aliskiren
US8119841B2 (en) * 2006-11-07 2012-02-21 Novartis Ag Crystalline forms of aliskiren hemifumarate
EP2089356B1 (en) * 2006-11-09 2012-04-25 Novartis AG Salt of aliskiren with orotic acid
JP5220025B2 (ja) * 2006-12-04 2013-06-26 プロメディオール, インコーポレイテッド 線維症疾患を処置するための併用療法
JP2010518147A (ja) * 2007-02-16 2010-05-27 ノバルティス アーゲー 有機化合物の使用
EP1972335A1 (en) * 2007-03-23 2008-09-24 Krka Solid dosage forms comprising aliskiren and pharmaceutically acceptable salts thereof
RU2363472C2 (ru) * 2007-05-22 2009-08-10 Государственное образовательное учреждение высшего профессионального образования "Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова Федерального агентства по здравоохранению и социальному развитию" Способ профилактики и лечения кардиоваскулярных осложнений у больных с хронической болезнью почек, находящихся на гемодиализе, имеющих анурию
US8497243B2 (en) * 2007-07-06 2013-07-30 Promedior, Inc. Methods and compositions useful in the treatment of mucositis
US9884899B2 (en) 2007-07-06 2018-02-06 Promedior, Inc. Methods for treating fibrosis using CRP antagonists
CN101883564B (zh) 2007-10-05 2013-10-16 阿尔茨海默病学会美国公司 使用(-)-尼伐地平对映体减少淀粉状蛋白沉积、淀粉状蛋白神经毒性和小神经胶质增生的方法
EP2062874B1 (en) 2007-11-20 2014-12-17 KRKA, tovarna zdravil, d.d., Novo mesto Process and intermediates for the preparation of aliskiren
EP2100599A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
RU2373932C1 (ru) * 2008-05-20 2009-11-27 Илья Николаевич Медведев Способ коррекции уровня микровезикул в крови при артериальной гипертонии
RU2372079C1 (ru) * 2008-05-20 2009-11-10 Илья Николаевич Медведев Способ коррекции уровня микровезикул в крови при артериальной гипертонии, дислипидемии и нарушении толерантности к глюкозе
JO3239B1 (ar) 2008-09-22 2018-03-08 Novartis Ag تركيبات جالينية من مركبات عضوية
RU2382644C1 (ru) * 2008-11-05 2010-02-27 Государственное образовательное учреждение высшего профессионального образования "Пермская государственная медицинская академия имени академика Е.А. Вагнера Федерального агентства по здравоохранению и социальному развитию" Способ коррекции гипертрофии левого желудочка у больных ибс в сочетании с гипертонической болезнью
SI2189442T1 (sl) 2008-11-20 2015-03-31 Krka, Tovarna Zdravil, D.D., Novo Mesto Postopek in intermediati za pripravo aliskirena
PT2405928T (pt) * 2009-03-11 2017-02-07 Promedior Inc Métodos de tratamento e de diagnóstico para patologias de hipersensibilidade
PT2405929T (pt) * 2009-03-11 2018-07-23 Promedior Inc Métodos de tratamento para distúrbios autoimunes
UA110323C2 (en) * 2009-06-04 2015-12-25 Promedior Inc Derivative of serum amyloid p and their receipt and application
HUE041034T2 (hu) * 2009-06-17 2019-05-28 Promedior Inc SAP-variánsok és alkalmazásuk
EP2510928A1 (en) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients
CN102247344A (zh) * 2011-05-30 2011-11-23 北京阜康仁生物制药科技有限公司 一种新型降血压组合物
CN102552277A (zh) * 2011-12-02 2012-07-11 邬林祥 氨氯地平、阿利可仑和氢氯噻嗪复方降压药物
CN102626391B (zh) * 2012-04-19 2013-07-10 海南美兰史克制药有限公司 一种阿利克仑氢氯噻嗪药物组合物脂质体固体制剂
GB201317373D0 (en) 2013-10-01 2013-11-13 Univ Dundee Treatment and prevention of cancer
CN111789843A (zh) * 2019-04-08 2020-10-20 深圳奥萨医药有限公司 含氨氯地平、氯噻酮和阿米洛利的药物组合物
KR102414285B1 (ko) * 2020-06-02 2022-06-28 이화여자대학교 산학협력단 플루나리진 또는 이의 약학적으로 허용 가능한 염을 유효성분으로 함유하는 골질환의 예방 또는 치료용 약학적 조성물

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5350771A (en) * 1989-03-22 1994-09-27 Peter K. T. Pang Method and treatment for hypertension using combination therapy involving exogenous calcium and calcium channel blockers
US5656650A (en) * 1990-12-14 1997-08-12 Smithkline Beecham Corp. Angiotensin II receptor blocking compositions
EP0565634B1 (en) * 1990-12-14 1999-03-17 Smithkline Beecham Corporation Angiotensin ii receptor blocking compositions
US5178877A (en) * 1991-01-04 1993-01-12 Abbott Laboratories Encapsulated renin inhibitor composition
US5114925A (en) * 1991-01-22 1992-05-19 Merck & Co., Inc. Renin inhibitors containing the 2-[[(2R,3S)-3-amino-4-cyclohexyl-2-hydroxy-1-butyl]thio)alkanoyl moiety and the corresponding sulfoxide and sulfone derivatives
US5202322A (en) * 1991-09-25 1993-04-13 Merck & Co., Inc. Quinazolinone and pyridopyrimidine a-II antagonists
US5256667A (en) * 1991-09-25 1993-10-26 Merck & Co., Inc. Quinazolinones and pyridopyrimidinones
US5292741A (en) * 1992-08-18 1994-03-08 Merck & Co., Inc. Macrocycles incorporating quinazolinones
MY119161A (en) 1994-04-18 2005-04-30 Novartis Ag Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities
EP0795327A1 (en) 1996-03-13 1997-09-17 Pfizer Inc. Use of Amlodipine for the treatment and prophylaxis of congestive cardiac failure of non-ischaemic origin
US8168616B1 (en) * 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
WO2002043807A2 (en) * 2000-12-01 2002-06-06 Novartis Ag Combinations of an angiotensin receptor antagonist and an anti-hypertensive drug or a statin, for the treatment of sexual dysfunction
DE60227679D1 (de) * 2001-09-11 2008-08-28 Asahi Kasei Pharma Corp Medizinische zusammensetzung zur prävention oder behandlung von zerebrovaskulären störungen
US7019010B2 (en) * 2001-09-27 2006-03-28 Novertis Ag Combinations
KR20100137026A (ko) * 2002-05-17 2010-12-29 노파르티스 아게 레닌 억제제, 칼슘 채널 차단제 및 이뇨제를 포함하는 약제학적 조성물

Similar Documents

Publication Publication Date Title
KR20100137026A (ko) 레닌 억제제, 칼슘 채널 차단제 및 이뇨제를 포함하는 약제학적 조성물
US20080027032A1 (en) Combinations comprising cox-2 inhibitors and aspirin
JP2010280708A5 (cg-RX-API-DMAC7.html)
CA2727326A1 (en) Dronedarone for the prevention of permanent atrial fibrillation
RU2009110452A (ru) Галеновые составы алискирена
AU2019397511B2 (en) Sulcardine administration for treatment of acute atrial fibrillation
US20160175286A1 (en) Selective at2 receptor agonists for use in treatment of cachexia
Zhang et al. Small-molecule integrated stress response inhibitor reduces susceptibility to postinfarct atrial fibrillation in rats via the inhibition of integrated stress responses
CA2739463C (en) Methods and compositions for treatment of acute heart failure
KR20110026421A (ko) 심장율동전환의 예방을 위한 드로네다론
KR20230024347A (ko) 급성 심방 세동의 치료를 위한 설카르딘 투여
CN102470138A (zh) 钠-质子交换蛋白抑制剂和二氢-1,3,5-三嗪胺衍生物的组合产品
JP2011517694A (ja) ドロネダロンと少なくとも1つの利尿薬の組み合わせおよびこの治療的使用
AU8081598A (en) Method for treating heart failure
CN101015556B (zh) 窦房结If电流抑制剂与钙抑制剂的组合以及含有它的药物组合物
Rabbani et al. The role of magnesium therapy in acute myocardial infarction
WO2003094924A1 (en) Combination therapy for treating cyclooxygenase-2 mediated diseases in patients at risk of thrombotic cardiovascular events
JP2012522024A (ja) 左旋性アムロジピン複合薬組成物
JP2006520343A (ja) 2−(ブチル−1−スルホニルアミノ)−n−[1(r)−(6−メトキシピリジン−3−イル)プロピル]ベンズアミド、医薬としてのその使用及び該化合物を含有する医薬製剤
JP5982715B2 (ja) 抗高血圧薬組成物
US20180311241A1 (en) Pharmaceutical synergistic combination
JP4872044B2 (ja) 心臓リモデリング抑制薬および心不全治療薬
Roy The atrial fibrillation and congestive heart failure (AF-CHF) trial
Barretto et al. Levosimendan treatment for acutely decompensated heart failure is as effective for Chagas disease patients as for patients with other etiologies
Brozena et al. A prospective study of out-patient continuous milrinone therapy in patients awaiting heart transplant